TScan Therapeutics reports Q1 2024 revenue decline, but lead products TSC-100 and TSC-101 are in Phase I clinical trials, and several analysts have issued "buy"
Biopharmaceutical company TScan Therapeutics (TCRX) focuses on T-cell receptor engineered T cell therapies for cancer treatment. Among analysts' ratings over the last quarter, 4 are "bullish" and 1 is "somewhat bullish." The 12-month price targets averaging $12.6 with high and low estimates at $15.00 and $10.00, respectively. The company's revenue declined by -91.68% in Q1 2024, but it has a strong net margin of -5,325.44% and ROE/ROA below industry standards. TCRX's lead products, TSC-100 and TSC-101, are in Phase I clinical trials. Several analysts have issued "buy" ratings with target prices ranging from $10.00 to $15.00.
August 13, 2024
4 Articles